Kao (4452) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
6 Nov, 2026Executive summary
9M net sales rose 7.1% YoY to ¥1,319.3bn, with 3.1% like-for-like growth; operating income increased 28.1% to ¥146.5bn.
Earnings growth reflected consumer-care momentum, improved Chemical profitability and an ¥11.5bn land-sale gain; FY operating-income guidance remains ¥190bn.
Financial highlights
9M reported sales growth included a 4.0% currency benefit; like-for-like growth comprised a 3.3% price increase and 0.2% volume decline.
Gross profit increased to ¥529.4bn and gross margin expanded 1.1 points to 40.1%; operating margin improved to 11.1%.
Income before taxes rose 24.5% to ¥148.7bn; net income increased 24.5% to ¥105.7bn, with ¥105.1bn attributable to owners, up 24.0%.
Basic EPS was ¥116.12 on a share-split-adjusted basis; EBITDA increased 20.0% to ¥214.3bn.
Q3 sales were ¥447.4bn, up 2.4% like-for-like; operating income rose 12.1% to ¥50.7bn and operating margin reached 11.3%.
Outlook and guidance
FY2026 guidance is unchanged: sales ¥1,800bn, operating income ¥190bn, income before taxes ¥193bn and net income attributable to owners ¥135bn; EPS forecast is ¥149.21.
Operating-income guidance is up ¥26.5bn YoY, or ¥15.1bn excluding the ¥11.5bn land-sale gain; expected earnings-power contribution exceeds ¥27.5bn against a ¥16.5bn raw-material cost impact.
Q4 priorities include strengthening earnings outside Japan, pricing and inventory actions in Chemicals, high-value-added products, Total Cost Reduction and electronic-material sales growth.
Q4 operating income is expected below prior year as delayed GC raw-material costs, overseas earnings-base initiatives and growth investments weigh on results.
K27 targets are record operating income above ¥211.7bn and ROIC of at least 11%; FY2026 ROIC forecast remains 10.5%.
Latest events from Kao
- Core income rose despite reform costs; FY2024 operating income is forecast at ¥130B.4452
Q4 2023 - Record profit and upgraded outlook driven by R&D and growth in dermacosmetics and semiconductors.4452
Q2 2026 - DX investment, empowered talent, and data-driven strategies fuel global growth and innovation.4452
Status update - Targets JPY 400B sales and 15% margin by 2027 via global brand focus and operational efficiency.4452
Status update - AI-powered marketing tools and global collaboration accelerate growth and profitability worldwide.4452
Status update - Strong sales and profit growth, aided by a land sale, with stable outlook despite global risks.4452
Q1 2026 - Profits and sales rose, with a share split and higher dividends planned for FY2026.4452
Q4 2025 - Profit and margin growth surged on reforms and premiumization, offsetting China cosmetics weakness.4452
Q3 2024 - H1 operating income up 68%, full-year outlook raised, but China remains a challenge.4452
Q2 2024